Nothing Special   »   [go: up one dir, main page]

CN111601590A - 一种海泽麦布片剂及其制备方法 - Google Patents

一种海泽麦布片剂及其制备方法 Download PDF

Info

Publication number
CN111601590A
CN111601590A CN201880073252.3A CN201880073252A CN111601590A CN 111601590 A CN111601590 A CN 111601590A CN 201880073252 A CN201880073252 A CN 201880073252A CN 111601590 A CN111601590 A CN 111601590A
Authority
CN
China
Prior art keywords
tablet
haezetimibe
haizumab
povidone
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880073252.3A
Other languages
English (en)
Inventor
丁立
代军
冯春荣
代常亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Hisun Pharmaceutical Co Ltd
Original Assignee
Zhejiang Hisun Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Hisun Pharmaceutical Co Ltd filed Critical Zhejiang Hisun Pharmaceutical Co Ltd
Publication of CN111601590A publication Critical patent/CN111601590A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

海泽麦布片剂、海泽麦布固体分散体组合物及其制备方法和用途。采用海泽麦布与辅料进行湿法制粒，干燥，整粒，压片得到海泽麦布片剂。

Description

PCT国内申请，说明书已公开。

Claims (28)

  1. PCT国内申请，权利要求书已公开。
CN201880073252.3A 2017-11-23 2018-11-23 一种海泽麦布片剂及其制备方法 Pending CN111601590A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017111833883 2017-11-23
CN201711183388 2017-11-23
PCT/CN2018/117086 WO2019101150A1 (zh) 2017-11-23 2018-11-23 一种海泽麦布片剂及其制备方法

Publications (1)

Publication Number Publication Date
CN111601590A true CN111601590A (zh) 2020-08-28

Family

ID=66630745

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880073252.3A Pending CN111601590A (zh) 2017-11-23 2018-11-23 一种海泽麦布片剂及其制备方法

Country Status (3)

Country Link
US (1) US11622939B2 (zh)
CN (1) CN111601590A (zh)
WO (1) WO2019101150A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3955912A4 (en) * 2019-04-17 2022-12-14 Cardiopharma, Inc. FIXED DOSE COMBINATION FOR BP AND CHOLESTEROL REDUCING AND METHOD OF MANUFACTURE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101993403A (zh) * 2009-08-11 2011-03-30 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
CN103655453A (zh) * 2013-12-27 2014-03-26 华润赛科药业有限责任公司 一种依折麦布药物组合物的制备方法
CN104490833A (zh) * 2014-12-11 2015-04-08 武汉武药科技有限公司 一种依折麦布口腔崩解片及其制备方法
WO2017111292A1 (ko) * 2015-12-22 2017-06-29 롯데정밀화학 주식회사 경구용 약제 조성물 및 그 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
EP2217214B1 (en) * 2007-12-10 2017-07-19 ratiopharm GmbH Pharmaceutical formulation comprising ezetimibe
JP2015527376A (ja) 2012-09-05 2015-09-17 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． アゼチジノン化合物の結晶及びその調製方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101993403A (zh) * 2009-08-11 2011-03-30 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
CN103655453A (zh) * 2013-12-27 2014-03-26 华润赛科药业有限责任公司 一种依折麦布药物组合物的制备方法
CN104490833A (zh) * 2014-12-11 2015-04-08 武汉武药科技有限公司 一种依折麦布口腔崩解片及其制备方法
WO2017111292A1 (ko) * 2015-12-22 2017-06-29 롯데정밀화학 주식회사 경구용 약제 조성물 및 그 제조방법

Also Published As

Publication number Publication date
US11622939B2 (en) 2023-04-11
US20210145754A1 (en) 2021-05-20
WO2019101150A1 (zh) 2019-05-31

Similar Documents

Publication Publication Date Title
US10166234B2 (en) Pharmaceutical preparation comprising phenylalanine derivative
CN106551912B (zh) 一种提高难溶性药物溶出度的方法
WO2017020841A1 (zh) 一种含有lcz696的药物组合物及其制备方法
US20190022008A1 (en) Apixaban solid composition and preparation method thereof
CN111888335A (zh) 一种托伐普坦的药物固体制剂及制备方法
CN103877051B (zh) 一种依折麦布片的制备方法
JP5367735B2 (ja) 錠剤の製造方法
CN104069500A (zh) 一种包含乐卡地平的药物组合物
CN107951841B (zh) 一种尼莫地平固体分散体及其片剂制备方法
CN111601590A (zh) 一种海泽麦布片剂及其制备方法
CN110638770A (zh) 他达拉非片剂的制备方法及以该方法制得的片剂
CN113827575A (zh) 一种利伐沙班片剂及其制备方法
CN103083326A (zh) 一种醋酸优力司特药物组合物
CN102218071A (zh) 一种微粉化地夫可特口服制剂及其制备方法
CN103006595B (zh) 制备醋酸优力司特片的方法
CN111467317B (zh) 一种含有阿托伐他汀钙的药物组合物及其制备方法
CN106880598B (zh) 一种依折麦布片剂
CN106860407B (zh) 一种利伐沙班片
CN114533677A (zh) 固体分散体、制剂、其制备方法及其应用
CN104666260B (zh) 一种依折麦布片剂
WO2018042168A1 (en) Stable pharmaceutical composition of vortioxetine hydrobromide
CN115317455B (zh) 一种药片含量均匀、易于溶出的瑞舒伐他汀钙片及其制备方法
CN112023056A (zh) 一种氟康唑药物组合物及其制备方法
CN104352465A (zh) 一种不含二氧化硅的琥珀酸普芦卡必利药物组合物及其制备方法
CN102805745B (zh) 一种伊潘立酮组合物及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination